Argenx SE 2024 AR2
The report highlights argenx's significant progress in 2024, achieving global product net sales of $2.2 billion, driven by the commercial expansion of VYVGART and VYVGART SC. The company secured FDA approval for VYVGART HYTRULO for chronic inflammatory demyelinating polyneuropathy (CIDP) and launched it in the U.S., while also obtaining approval for VYVGART in Japan for primary immune thrombocytopenia (ITP). Additionally, argenx advanced its clinical pipeline, initiating Phase 3 trials for empasiprubarb in multifocal motor neuropathy (MMN) and starting proof-of-concept studies for ARGX-119 in congenital myasthenic syndrome (CMS) and amyotrophic lateral sclerosis (ALS). The company also reported its first annual profit of $833 million and expanded its workforce to 1,599 employees.
Company: Argenx SE
Sector: Health Care
Country: Netherlands
Year: 2024
Type: AR2
Pages: 384
Argenx SE
Annual Report
The report highlights argenx's significant progress in 2024, achieving global product net sales of $2.2 billion, driven by the commercial expansion of VYVGART and VYVGART SC. The company secured FDA approval for VYVGART HYTRULO for chronic inflammatory demyelinating polyneuropathy (CIDP) and launched it in the U.S., while also obtaining approval for VYVGART in Japan for primary immune thrombocytopenia (ITP). Additionally, argenx advanced its clinical pipeline, initiating Phase 3 trials for empasiprubarb in multifocal motor neuropathy (MMN) and starting proof-of-concept studies for ARGX-119 in congenital myasthenic syndrome (CMS) and amyotrophic lateral sclerosis (ALS). The company also reported its first annual profit of $833 million and expanded its workforce to 1,599 employees.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees